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Abstract 
Alpha-toxigenic Clostridium septicum (CS), the cause of turkey cellulitis, results in 
devastating mortality with high costs for the industry. Various vaccinations have been evaluated 
to prevent this disease with moderate success. Ability of a CS bacterin-toxoid, in conjunction 
with adjuvants such as aluminum hydroxide, mannoslyated chitosan, or a water-in-oil Seppic 
Montanide 71 R VG adjuvant (OE) to induce immunity was evaluated in a 7-week study 
(Experiment 1). Poults (20/group) were vaccinated day-of-hatch, boosted at 5 weeks-of-age and 
compared to unvaccinated controls. Antibody levels were determined by ELISA for all 
experiments. In experiment 1, initial vaccination with the OE resulted in significantly (P<0.05) 
higher antibody levels at 5 weeks-of-age, and at 7 weeks-of-age OE resulted in numerically 
increased antibody levels compared to all vaccinated groups. Efficacy of the OE vaccine was 
then evaluated in two field trials (Experiment 2 and 3) with treatments including a non-
vaccinated control group and a vaccinated group. Non-vaccinates were marked by removal of the 
dewclaw at the hatchery and comingled during growout (Experiment 2 and 3).  Experiment 2 
consisted of 3 houses: House 1 (HS1), House 2 (HS2), and House 3 (HS3). Mortality associated 
with cellulitis was recorded once the first case was observed. Blood samples were obtained at 8, 
12, and 16 weeks-of-age. Antibody levels (S/P ratio) in vaccinated groups for weeks 12 and 16 
were significantly higher (P<0.05) than the control groups for all 3 houses. In HS1 and HS2, low 
CS-associated mortality was observed and there was no significant difference in mortality/total 
(%) between control and vaccinated group. In HS3, control mortality/total (%) was significantly 
(P<0.001) higher than mortality in vaccinated turkeys. Experiment 3 consisted of 6 farms with 1-
4 houses/farm. Vaccination significantly (P<0.05) reduced CS-related mortalities as compared to 
controls in 5 of 6 farms in experiment 3 and antibody titers were significantly (P<0.05)  higher in 
vaccinated turkeys at 12 and 16 weeks for all 6 farms. Based on these results, W/O emulsion 
  
vaccines, such as this alpha-toxin bacterin-toxiod with Montanide 71 R VG adjuvant, can be 
used to increase antibody titers and may reduce related mortalities in the field. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2018 by Brittany Graham 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acknowledgements  
I would like to thank my family at the Poultry Health Laboratory for the guidance and 
support over the years. Thank you Cheryl, Howard, Amanda, Juan David, Mikayla, Paula and 
Adil for always being eager to help. We make a fantastic team! To Lucas and Kyle, I cannot 
thank you enough for what you both have done for me. You both contributed to the success of 
this project, as well as many others. It has been a privilege to learn and grow as scientists with 
you both.  
I’d like to especially thank Dr. Billy M. Hargis. Thank you for the opportunity to attend 
graduate school and work in your laboratory. Some people go their entire lives without knowing 
what they are passionate about, but because of you and this opportunity, that will not be me. 
Thank you for genuinely caring for and believing in your students. To Dr. Guillermo Tellez and 
Dr. Lisa Bielke, thank you both for being kind, exceptional mentors.  
To my mom and sister, thank you for always loving and believing in me no matter what 
the endeavor may be. To the Graham family, you all are intensely driven which motivates me to 
work harder each and every day.   
 
 
 
 
 
 
 
 
 
  
Dedication 
I would like to dedicate this thesis to my husband and my grandparents. Lucas, you 
inspire and challenge me daily. You believe in me regardless of the situation. Without your true 
love and friendship, I would not be where I am today. I love you more than you will ever know! 
Thank you, Nana and Papa, for being the most outstanding role models over the last 24 years. I 
couldn’t have done any of this without you.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table of Contents 
 
Chapter I. Introduction ................................................................................................................ 1 
Chapter II. Literature Review ..................................................................................................... 2 
Clostridium septicum and other related Clostridial species ................................................... 2 
Clostridium septicum Pathogenesis ........................................................................................... 5 
Outside-In Theory ..................................................................................................................... 7 
Inside-Out Theory ..................................................................................................................... 8 
Experimental Vaccines ............................................................................................................. 9 
Prevention and Treatment Methods ...................................................................................... 12 
Conclusion ................................................................................................................................ 14 
References ................................................................................................................................ 15 
Chapter III. Evaluation of the Efficacy of a Candidate Turkey Cellulitis/Dermatitis Oil 
Emulsion Vaccine on Immune Response, Morbidity, and Mortality under Laboratory and 
Commercial Conditions .............................................................................................................. 19 
ABSTRACT ............................................................................................................................. 20 
INTRODUCTION ................................................................................................................... 22 
MATERIALS AND METHODS ........................................................................................... 23 
Bacterial isolates ................................................................................................................... 23 
CS bacterin-toxoid Vaccine Preparation ............................................................................. 24 
Indirect Enzyme-Linked Immunosorbent Assay (ELISA) .................................................. 24 
EXPERIMENTAL DESIGN .................................................................................................. 25 
Laboratory Trial.................................................................................................................... 25 
Field Trial 1 .......................................................................................................................... 25 
Field Trial 2 .......................................................................................................................... 26 
Statistical Analysis ................................................................................................................ 26 
RESULTS AND DISCUSSION.............................................................................................. 27 
References ................................................................................................................................ 31 
Chapter IV. Conclusion .............................................................................................................. 37 
Appendix ...................................................................................................................................... 38 
 
 
 
  
List of Tables 
Table 1. Antibody response to Clostridium septicum alpha toxin following vaccination with 
various CS bacterin-toxoid/adjuvant combinations (Experiment 1) ............................................. 33 
Table 2. Lesions at vaccine injection site evaluated post-mortem at 7 weeks-of-age (Experiment 
1) ................................................................................................................................................... 33 
Table 3. Cellulitis-related mortalities and antibody response Clostridium septicum alpha toxin at 
8, 12, and 16 weeks post-vaccination (Experiment 2) .................................................................. 34 
Table 4. Antibody response at 8, 12, and 16-20 weeks-of-age (Experiment 3) ........................... 35 
Table 5. Late cellulitis-associated mortalities (Experiment 3) ..................................................... 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
Chapter I. Introduction 
 
Turkey cellulitis, also referred to as clostridial dermatitis, is a problematic disease with 
prevalence escalating over the last two decades in the United States (Lighty et al., 2016).  Peak 
incidence occurs in turkey flocks around 13-18 weeks-of-age (Clark et al., 2010). Clostridium 
perfringens and Clostridium septicum are opportunistic pathogens that have been isolated from 
cellulitis lesions (Thachil et al., 2010), however, C. septicum has been identified as the primary 
etiology responsible for cellulitis in commercial turkeys (Tellez et al., 2009).  Controlling C. 
septicum is difficult due to the probability of the pathogen being a commensal organism within 
the gastrointestinal tract of healthy animals (Clark et al., 2010). The spores can also remain 
dormant in an unfavorable environment and then thrive when growth conditions are optimal 
(Clark et al., 2010). Immunosuppression or stressful conditions followed by challenge with C. 
septicum, a ubiquitous pathogen, can prompt disease (Clark et al., 2010). Development of 
clinical signs and mortalities related to cellulitis commonly result in the affected flock being 
treated with antibiotics (Clark et al., 2010).  Proper management practices and antibiotic therapy 
have proven to reduce the incidence, but does not eliminate the disease.   
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Chapter II. Literature Review 
 
Clostridium septicum and other related Clostridial species  
 
 Clostridium septicum is a Gram-positive, anaerobic spore forming bacillus that produces 
four toxins: alpha-toxin, beta-toxin, gamma-toxin, and delta-toxin (Hatheway 1990) with alpha-
toxin as the most necrotizing (Tweten et al., 2001). Bacterial toxin production can vary based on 
temperature, time, pH, and availability of nutrients (Lalitha et al., 2005). In turkeys, C. septicum 
infection is associated with turkey cellulitis (Tellez et al., 2009; Thachil et al., 2013). Areas 
affected include the breast, tail, and thigh area where gas produced by the actively replicating 
anaerobic bacteria accumulates at the site of infection (Clark et al., 2010). In early observed 
cases, C. perfringens Type A was isolated from lesions containing gelatinous fluid under the skin 
with the musculature having a dark or greenish appearance (Carr et al., 1995).  Other etiologies, 
including C. perfringens, have been categorized as a pathogen associated with turkey cellulitis 
(Gomis et al., 2001; Gornatti-Churria et al., 2018), however, C. septicum has been proven to be 
the principal causative agent (Tellez et al., 2009) and the accumulation of C. septicum alpha 
toxin is responsible for accompanying clinical signs (Kennedy et al., 2005).  
Following subcutaneous challenge with 0.5, 1, 2, or 3mL of C. perfringens or C. septicum 
spore culture, C. septicum spore challenge group had more associated mortalities within 48h in 
both 3-week and 7-week old turkeys than the C. perfringens spore challenge group (Thachil et 
al., 2010). Gross macroscopic lesions on breast and tail area were observed in both challenge 
groups although more severe lesions were detected in the C. septicum challenge group (Thachil 
et al., 2010).  Hemorrhage and edema was associated with both the dermis and subcutis, with 
heterophil infiltration more pronounced in the C. septicum 1mL challenge group and gas 
formation identified heavily in the C. septicum 3mL challenge group (Thachil et al., 2010). In 
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turkeys challenged with the higher doses of C. septicum, notable cellular necrosis and 
myonecrosis was observed. Within these necrotic regions, there were high numbers of rod 
shaped bacteria and low amounts of inflammatory cells (Thachil et al., 2010). There was an 
inverse relationship noted between heterophil infiltration and actively replicating bacteria within 
the tissue of C. septicum infected turkeys, the group that showed classical cellulitis mortality 
response and clinical signs (Thachil et al., 2010). To investigate the incidence and relationship 
between C. septicum in broilers and turkeys, 109 C. septicum isolates were recovered from both 
turkey and broiler flocks that had a history of dermatitis or cellulitis (Neumann et al., 2009). Out 
of the analyzed sequences, only one sequence showed commonality between the broiler and 
turkey strain suggesting isolates show specificity (Neumann et al., 2009).  
In broiler chickens, gangrenous dermatitis is caused by both C. perfringens and C. 
septicum around 6 weeks-of-age (Li et al., 2010). Microscopic evaluation of gangrenous 
dermatitis lesions reveal gas and fluid accumulation, necrosis and heterophil infiltration (Li et al., 
2010). Gangrenous dermatitis lesions observed in the breast, abdomen and thigh area were 
heavily discolored with emphysema and serosanguinous fluid (Li et al., 2010; Lee et al., 2012). 
Intestinal observations reveal severe hemorrhaging thus increasing the permeability of the 
intestinal epithelial barrier, allowing potentially allowing for enteric translocation of clostridial 
pathogens to the submucosa, and potentially systemically (Li et al., 2010). To identify causative 
pathogens associated with gangrenous dermatitis after immunocompromising broilers with an 
infectious bursal disease virus vaccination at 14 days, Staphylococcus aureus and C. septicum 
isolates, alone or in combination, were administered intramuscularly or subcutaneously to 4-
week-old broilers (Wilder et al., 2001). Elevated mortality was observed in the C. septicum and 
S. aureus challenge groups. However, C. septicum alone was not responsible for dermatitis 
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associated lesions in this experiment (Wilder et al., 2001).   Li et al., (2010) identified that 
gangrenous dermatitis affected broilers had significantly higher C. perfringens serum antibodies 
than the non-infected broilers. Interestingly, there was no difference in C. septicum serum 
antibodies or Eimeria spp. antibodies between the infected and non-infected group, although 
antibody levels were high in both (Li et al., 2010). This indicates that C. perfringens may be the 
etiology responsible for gangrenous dermatitis associated lesions and mortalities. In another 
study, serum samples were collected from non-affected and gangrenous cellulitis affected 
broilers at 35 days-of-age where the non-affected broilers had higher antibody levels to C. 
perfringens alpha-toxin and netB than the broilers with clinical signs (Lee et al., 2012). The 
authors hypothesized that the non-affected broilers had elevated antibodies levels which 
protected them from acquiring the disease (Lee et al., 2012).  
In ruminants, blackleg is caused by C. chauvoei, an anaerobic, spore-forming, bacillus 
which is generally present in the environment that primarily affects cattle (Useh et al., 2006; 
Uzal et al., 2012) and sheep (Useh et al., 2006). It is widely believed that C. chauvoei spores 
reside in tissues and germinate at the site of an injury (Useh et al., 2006). The pH and oxygen 
availability within damaged muscle continues to change due to replication of C. chauvoei, 
creating an environment where the pathogen can efficiently propagate (Useh et al., 2006). C. 
chauvoei produces gamma toxins, beta-toxins, hemolysins, and neuraminidases (Useh et al., 
2003). C. septicum has also been isolated from blackleg lesions in cattle but differs from C. 
chauvoei based on the presence of edema which is generally not apparent with C. chauvoei 
infections (Hatheway, 1990). To prevent blackleg, cattle are vaccinated annually with formalin 
inactivated bacterins and if an infection occurs, animals are typically treated with penicillin 
(Useh et al., 2006).  
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Opportunistically pathogenic clostridial species are nearly ubiquitous in areas where 
commercial poultry or livestock are raised.  As many or all of these species have a primary niche 
of amplification within the gastrointestinal tract, either ingestion of spores or sporulation of 
living vegetative cells within the digesta provide a nearly constant source for potential 
translocation across the enteric epithelial barrier.  When these spores, perhaps carried by the 
circulation, are present in damaged tissues with relative anoxia, they may then have the potential 
to germinate, replicate, and generate local toxin-associated necrosis, thereby increasing the 
ability of these organisms to anaerobically continue to grow.  These exotoxins, such as alpha 
toxin produced by C. septicum, can also be responsible for initial lesions and ultimately mortality 
related to localized tissue diseases. 
Clostridium septicum Pathogenesis  
 
As described above, turkey cellulitis is caused by the accumulation of Clostridia, 
specifically C. septicum, in lesions leading to edema and inflammation (Clark et al., 
2010).  Lesions containing fluid and gas caused by C. perfringens and C. septicum are often 
similar, but mortality is more frequent in C. septicum infected turkeys (Thachil et al., 2010). 
Pathogens can enter circulation by translocating through the intestinal barrier, through broken 
skin or lesions, or by oral inoculation followed by subsequent physical trauma or gut leakage 
(Clark et al., 2010).  With little known about the mechanisms of this disease, isolation and 
identification of the causative agent was imperative to further understand the pathogen most 
commonly associated with turkey cellulitis. In 2009, C. septicum was determined to be the most 
common pathogen related to turkey cellulitis in commercially produced turkeys (Tellez et al., 
2009).   
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C. septicum alpha-toxin is structurally similar to Aeromonas hydrophila aerolysin 
(Ballard et al., 1995) being a pore-forming cytolysin where this specific toxin attaches to 
glycosylphosylinositol (GPI) protein receptors (Gordon et al., 1999; Kennedy et al., 2005).  This 
attachment and pore formation results in cell lysis. Kennedy et al. (2005) determined that the 
primary virulent attribute of C. septicum is related to alpha-toxin activation and production.  Pore 
forming toxins, such as C. septicum alpha toxin, affect the permeability of the host cell 
membrane by attaching and creating a pore (Popoff et al., 2014) leading to necrosis or apoptosis 
(Bischofberger et al., 2012). Pore size ranges from 1.3-1.6 nm in diameter (Knapp et al., 2009). 
Alterations in permeability caused by pore formation disrupt several cellular interactions, 
including osmotic pressure and ion regulation within the cytosol. When exposed to certain pore 
forming proteins, pores are created in low numbers on the membrane and can be repaired via 
calcium dependent mechanisms (Babiychuk et al., 2011). This mechanism has not been 
evaluated for C. septicum alpha toxin although the probability of membrane repair occurring 
after encounter with pore forming toxins is minimal due to the rapid nature of pore formation 
(Bischofberger et al., 2012), such as with C. septicum alpha toxin. Increased pore formation 
associated with C. septicum alpha toxin may hinder the cell’s ability to self-repair due to the 
accumulation of toxin.  
Kennedy et al., (2009) analyzed high mobility group box 1 (HMGB1), a protein that 
binds to receptor for advanced glycation end products (RAGE) instigating an inflammatory 
cascade that signals necrosis in adjacent cells (Scaffidi et al., 2002), for protein expression within 
the nucleus and the cytoplasm to determine if C. septicum alpha toxin induces HMGB1 
expression in a target cell. A murine myoblast cell line was used with treatments consisting of a 
non-treated control, a group treated with 0.1µg/mL alpha toxin, and a group treated with 1µg/mL 
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alpha toxin (Kennedy et al., 2009). Translocation of HMGB1 into the cytoplasm only occurred in 
the 1µg/mL treated group indicating that C. septicum alpha toxin at that level initiates necrosis 
within cells induced by Ca2+ level changes within the cell (Kennedy et al., 2009). Necrosis 
associated with C. septicum infections is due to HMGB1 expression by damaged cells, ionic 
changes caused by pore formation, and other regulatory changes within the cell (Kennedy et al., 
2009). Although lethality of C. septicum alpha toxin has been evaluated, the primary route of 
transmission or portal of entry for turkey cellulitis is still being investigated.  
Outside-In Theory 
 
 Clostridium septicum is the primary etiology causing turkey cellulitis (Tellez et al., 2009) 
though the portal of entry is not fully understood. This bacterium could potentially enter the host 
via puncture wounds or scratches (Clark et al., 2010) suggesting that the pathogen could 
potentially enter from the “outside”. In an experiment, day-of-hatch poults were subcutaneously 
injected in the breast area with C. septicum supernatant, neat C. septicum culture, or a 
conjunction of supernatant and convalescent antiserum (Tellez et al., 2009). Supernatant alone 
induced classical cellulitis clinical signs within 2h of inoculation (Tellez et al., 2009). No 
mortalities occurred 24h post-inoculation in the C. septicum supernatant only group. Supernatant 
with various dilutions of the convalescent antisera did not result in any lesions or mortality. 
However, injection with the C. septicum neat culture resulted in 78.5% mortality. Each affected 
poult had inflammation of the lungs, heart, and peritoneum similarly to observed cellulitis cases. 
Since morbidities, but no mortalities occurred in the supernatant only group, Tellez et al. 
suggested that the toxin produced by C. septicum may not be responsible for associated 
mortalities.  However, subcutaneous challenge with neat C. septicum culture was resulted in high 
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mortality which may indicate the bacteria were replicating quickly thus producing high 
concentrations of exotoxins.  
Thachil et al., (2013) investigated immune response post-vaccination with a C. septicum 
bacterin-toxoid oil emulsion vaccine with a subsequent challenge in the breast area in 
commercial turkeys. In this study, 24 hours post challenge in the breast area, there was 100% 
mortality in the control group (Thachil et al., 2013) providing further evidence that C. septicum 
can enter through openings in the skin. Reproduction of disease and mortality via subcutaneous 
challenge indicates C. septicum could enter through a puncture or wound, such as observed with 
a needle during challenge. In the field, this may be via scratches, abrasions, or cuts on the 
animal.   
Inside-Out Theory 
 
 Clostridial species are ubiquitous; therefore, disease may not be apparent until stress 
induces intestinal inflammation ultimately resulting in gut leakage allowing the passage of the 
pathogen into circulation (Gornatti-Churria et al., 2018). Once in circulation, cells may proceed 
to the site of damage or bruising where replication and toxin production likely occur (Clark et al., 
2010). Braxy in sheep and calves, or inflammation of the abomasum caused by a C. septicum 
infection, often results in septicemia and high mortality rates (Songer 1996). Intestinal barrier 
failure allows for the propagation of diseases related to C. septicum, such as cellulitis. 
 Cellulitis has not been successfully recreated with an oral challenge model. An 
experiment was conducted to determine the effect of dexamethasone treatment, an 
immunosuppressant, on mortality associated with C. perfringens and C. septicum challenge 
(Thachil et al., 2014). In this experiment, oral challenge with C. perfringens or C. septicum at 
both ~107 and 109 cfu/bird did not cause related mortalities in the control or dexamethasone 
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treated group. However, subcutaneous challenge with low dose of C. perfringens resulted in 0% 
mortality in both groups while the high dose caused 42% mortality in the positive control group 
and 100% mortality in the dexamethasone treated group (Thachil et al., 2014). A subcutaneous 
challenge of the low dose C. septicum resulted in 16% morality in the controls and 83% 
mortality in the dexamethasone group (Thachil et al., 2014). The high dose C. septicum 
subcutaneous challenge caused 100% mortality in both the control group and dexamethasone 
treated group. Dexamethasone treatment in conjunction with the oral challenge had no effect on 
mortality (Thachil et al., 2014) providing more evidence for the “outside-in” theory. Disease may 
not have been observed in the orally challenged group because these animals were not punctured 
while the subcutaneously injected turkeys were subjected to dermal puncture at challenge. A 
replicate experiment should be conducted to determine if oral challenge followed by sham 
subcutaneous challenge (no organism) induces cellulitis. This would provide more information 
for the argument of “outside-in” versus “inside-out”.  
Experimental Vaccines  
 
Toxoid vaccinations for various Clostridial diseases in humans (Kotloff et al., 2000) and 
livestock (Hammer et al., 2007) have been effective. Blackleg in cattle and ruminant animals 
caused by Clostridium chauvoei is controlled frequently with vaccines (Useh et al., 2003). A 
variety of toxoid vaccines are administered to prevent blackleg consisting of seven Clostridium 
isolates, although C. chauvoei and C. septicum are the two that calves are required to be 
vaccinated for (Uzal et al., 2012). C. chauvoei spores within the environment can be ingested, 
spread throughout circulation and reside in muscular tissue (Useh et al., 2006.). Once an injury 
occurs around where the spores are located, blackleg symptoms and mortality ensue (Useh et al., 
2006). However, a toxoid vaccine that provides optimal protection without antibiotic treatment 
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under commercial conditions has not been discovered for turkey cellulitis.  Experimental 
vaccinations for turkey cellulitis have included inactivated C. perfringens and C. septicum cells 
and toxins alone and in combination (Tellez et al., 2009; Thachil et al., 2012; Thachil et al., 
2013).  The antigen can be administered as an inactivated bacterin-toxoid or toxoid which will 
stimulate an immune response, specifically antibody production, but not cause infection in the 
animal. A C. perfringens and C. septicum toxoid vaccine subcutaneously administered at 6 
weeks-of-age significantly reduced mortality and penicillin usage, and significantly increased 
serum antibody levels to C. septicum and C. perfringens alpha-toxin in commercial turkeys 
(Thachil et al., 2012).  The mortality percentage in the nonvaccinated group was 9.4% and 7.4% 
in the vaccinated group indicating that the vaccination is providing immune protection and 
preventing mortalities related to cellulitis (Thachil et al., 2012).  There were 547 packs of 
penicillin used over 59 days in the nonvaccinated group compared to 361 packs of penicillin 
used over 31 days in the vaccinated group (Thachil et al., 2012).  Vaccination reduced penicillin 
usage days by 50% over the 22- week period although vaccination did not eliminate the need for 
penicillin treatment.  Although the C. perfringens and C. septicum toxoid vaccination provided 
significant protection, this vaccination alone cannot fully control or eliminate this disease.   
Although not proven, the possible mode of action for oil emulsion vaccines may be the 
ability of creating a depot effect at the site of injection where the antigen is slowly released and 
presented to the immune system (Aucouturier et al., 2001).  Thachil et al., (2013) conducted an 
experiment utilizing a C. septicum toxoid oil emulsion vaccine. Turkeys were vaccinated with a 
1mL dose (1.5g of toxoid) or 2mL dose (3g of toxoid) at 6 weeks-of-age (Thachil et al., 2013). A 
group of turkeys were boosted at 14 days post-vaccination. Antibody levels were significantly 
different between both vaccinated groups and the control groups at both doses as expected. Two 
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field studies were conducted to test the effects of the C. septicum bacterin-toxoid. In field study 1 
and 2, turkeys were vaccinated with the 1mL dose at 6 weeks-of-age. Cellulitis associated 
mortality was reported at 12.1% for the control group and 10.5% for the vaccinated group. The 
vaccinated turkeys had significantly less mortalities reported and were administered penicillin 40 
days less than the control.  In field study 2, mortality in the control group was 1.68% versus 
0.87% for the vaccinated group (Thachil et al., 2013). This indicates that this C. septicum 
bacterin-toxoid has protective effects against cellulitis in the field, but does not fully eliminate 
the use of antibiotics or mortality occurrence.  
A C. septicum bacterin-toxoid vaccine has been evaluated using aluminum hydroxide as 
an adjuvant (Tellez et al., 2010).  To test the ability of inactivated C. septicum vaccine, 10-week-
old turkeys were vaccinated with a formalin inactivated C. septicum bacterin-toxoid with 
aluminum hydroxide included as the adjuvant (Tellez et. al, 2009).  Vaccinated turkeys had 
significantly higher C. septicum antibody levels than the nonvaccinated turkeys (Tellez et al., 
2009). Vaccination with C. septicum bacterin-toxoid induces an immune response regardless of 
the adjuvant although protection may vary greatly between the adjuvants used.  
Lancto et al. (2014) evaluated the efficacy of a noncytolytic C. septicum alpha toxin to 
provide protection against C. septicum challenge. Challenge related mortalities were significantly 
lower in the noncytolytic C. septicum alpha toxin group when compared to non-vaccinated 
controls and there were numerically fewer mortalities within the C. septicum alpha toxin-
vaccinated group, although not significant (Lancto et al., 2014). The authors suggested that the 
safety concerns and cost to produce the recombinant vaccine are lower than for the bacterin-
toxoid vaccine and even indicate that a water administration with a vector expressing alpha toxin 
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antigen would be a viable vaccine alternative to the bacterin-toxoid preparation (Lanco et., 
2014).  
Prevention and Treatment Methods 
 
Antibiotics, including penicillin and lincomycin, and/or iodine are administered in the 
drinking water (Lighty et al., 2016) at onset of cellulitis-related mortalities and are provided until 
cellulitis lesions and mortalities are absent for at least 72 hours (Clark et al., 2010). Currently, 
the only effective treatment for turkey cellulitis is antibiotic therapy. Few alternative treatment 
and prevention approaches have been investigated. Dexamethasone, a synthetic glucocorticoid, 
causes immunosuppression in turkeys (Huff et al., 2013; Thachil et al., 2014) and increases 
intestinal leakage and bacterial translocation to the liver in chickens (Vicuna et al., 2015). It has 
also been shown to increase the incidence of turkey cellulitis mortalities (Huff et al., 2013; Huff 
et al., 2014) To evaluate the effects of yeast extract in the feed or vitamin D in the drinking water 
at reducing the incidence of cellulitis associated with stress, turkeys were administered 
dexamethasone intramuscularly in conjunction with yeast extract or vitamin D supplementation 
(Huff et al., 2014). No cellulitis-related mortalities occurred in the yeast extract treated group 
however, 47% of mortalities in the vitamin D treated group had characteristic cellulitis lesions 
(Huff et al., 2014). Administration of yeast extract in the feed at the late stages of production 
reduced incidence of cellulitis breakout in a flock although further studies need to be conducted 
to determine if yeast extract supplementation can prevent cellulitis in a challenge model. 
Direct-fed microbials are probiotics included in the diet that are beneficial to the host 
(Lee et al., 2010). The addition of a commercially available direct-fed microbial significantly 
reduced the presence of C. perfringens in the ceca and in the feces compared to a non-treated 
group (Rahimi et al., 2011).  Commercially, for cellulitis prevention, selected Bacillus isolates 
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have been included in the diet, although this does not fully avert the disease (Clark et al., 2010). 
Periodic inclusion of direct-fed microbial probiotics would provide flocks with beneficial 
bacteria that may prevent colonization of potentially harmful bacteria, such as C. septicum.  
In 2008, a meeting was held by collaborators in the industry to discuss and assemble 
prevention measures for producers to ultimately minimize the risk of disease and mortality 
associated with turkey cellulitis (Clark et al., 2010). A few recommendations included 
continuous education for farmers and others involved with turkey production, antibiotic 
treatment (dose, timing, type), immediate removal of any mortalities, and improved management 
practices to reduce the impact of environmental related factors (Clark et al., 2010).  In the United 
States, many commercial turkey producers continuously reuse litter and the build-up of used 
litter is correlated with turkey cellulitis (Clark et al., 2010). In Europe, turkey cellulitis is not an 
apparent threat to the turkey industry due to the all-in, all-out type of production systems, 
including complete cleanout and disinfection, that has been adopted (Clark et al., 2010). Reusing 
litter in the US, especially after a flock with high incidence of cellulitis, possibly subjects 
subsequent flocks to a challenge with the pathogenic organism that is present in the environment. 
Similarly, to the experimental breast area challenge, the flocks raised on reused litter may be 
naturally challenged through cuts or scratches on the skin. Complete removal of used litter and 
replacement with fresh litter may be necessary to reduce disease related to litter quality.  A study 
conducted comparing control farms with high incidence farms determined that elevated soil pH, 
high humidity levels within the barn, and the presence of a litter composting pile 200 feet from 
the barn increased the occurrence of turkey cellulitis (APHIS, 2012).  Barn management 
practices can be improved, but these practices are difficult to implement across the United States. 
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Conclusion 
 
 Clostridia are ubiquitous and are able to reside in the environment for extended periods of 
time. Commercial turkeys are frequently exposed to C. septicum, the pathogenic etiology linked 
to turkey cellultis, most frequently by injury to the dermis where this anaerobic, highly toxigenic 
rod replicates rapidly at the site of entry. In livestock, clostridial-related diseases can be 
prevented with vaccines and controlled with antibiotics. However, numerous vaccinations are 
difficult for commercial turkey producers because of the large labor cost attributed to handling 
each turkey. Experimental cellulitis vaccines have been evaluated with moderate success due to 
the need of intermittent treatment with antibiotics even after vaccination. Evaluating the efficacy 
of multiple adjuvants with a C. septicum bacterin-toxoid can provide implications for which 
vaccine to use in the field. 
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ABSTRACT 
 
Alpha-toxigenic Clostridium septicum (CS), the primary etiology of turkey cellulitis, results in 
devastating mortality. Various experimental vaccines have been evaluated to prevent this disease 
with variable but partial success. The ability of a CS bacterin-toxoid, in conjunction with 
adjuvants such as aluminum hydroxide, mannoslyated chitosan, or a water-in-oil Seppic 
Montanide 71 R VG adjuvant (OE) to induce immunity was evaluated in a 7-week study 
(Experiment 1). Poults (20/group) were vaccinated on day-of-hatch, boosted at 5 weeks-of-age 
and compared to unvaccinated controls. Antibody levels were determined by ELISA for all 
experiments. In experiment 1, initial vaccination with the OE resulted in significantly (P<0.05) 
higher antibody levels at 5 weeks-of-age, and at 7 weeks-of-age OE resulted in numerically 
increased antibody levels compared to all vaccinated groups. Efficacy of the OE vaccine was 
then evaluated in two field trials (Experiments 2 and 3) with treatments including a non-
vaccinated control group and a vaccinated group (~50% each). Non-vaccinates were marked by 
dewclaw removal at the hatchery and were comingled during growout (Experiments 2 and 3).  
Experiment 2 consisted of 3 houses: House 1 (HS1), House 2 (HS2), and House 3 (HS3). 
Mortality associated with cellulitis was recorded once the first case was observed. Blood samples 
were obtained at 8, 12, and 16 weeks-of-age. Antibody levels (S/P ratio) in vaccinated groups for 
weeks 12 and 16 were significantly higher (P<0.05) than the control groups for all 3 houses. In 
HS1 and HS2, low CS-associated mortality was observed and there was no significant difference 
in mortality/total (%) between control and vaccinated group. In HS3, control mortality (%) was 
significantly (P<0.001) higher than mortality in vaccinated turkeys. Experiment 3 consisted of 6 
farms with 1-4 houses/farm. Vaccination significantly (P<0.05) reduced CS-related mortalities as 
compared to controls in 5 of 6 farms in experiment 3 and antibody titers were significantly 
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(P<0.05)  higher in vaccinated turkeys at 12 and 16 weeks for all 6 farms. Based on these results, 
W/O emulsion vaccines, such as this alpha-toxin bacterin-toxiod with Montanide 71 R VG 
adjuvant, can be used to increase antibody titers and may reduce related mortalities in the field. 
Keywords: oil-emulsion vaccine; turkey cellulitis; Clostridium septicum; alpha-toxin; antibody 
titer 
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INTRODUCTION 
 
Turkey cellulitis or clostridial dermatitis is primarily caused by Clostridium septicum (Tellez et 
al., 2009), a Gram positive, anaerobic rod primarily affecting commercial turkey flocks later in 
production (Clark et al., 2010). The incidence of cellulitis is costly due to the increase in 
production expenses at the onset of disease (Lighty et al., 2016). Cellulitis lesions occur in areas 
such as the breast region where discoloration, edema and gas accumulation are commonly 
observed (Clark et al., 2010). Pathogens, such as C. perfringens, have been affiliated with 
cellulitis, however C. septicum alpha toxin is the most virulent exotoxin responsible for necrosis 
associated with C. septicum infections (Kennedy et al., 2005). Subcutaneous challenge models 
(Tellez et al., 2009; Thachil et al., 2010; Thachil et al., 2014) have been more effective than oral 
challenge models (Thachil et al., 2014) possibly indicating that C. septicum primarily enters the 
animal through scratches or punctures of the skin rather than by oral inoculation, although the 
possibility of systemic seeding due to enteric translocation has not been eliminated. C. septicum 
is a ubiquitous pathogen which makes this disease difficult to prevent or control under 
commercial conditions (Clark et al., 2010). Antibiotic therapy can effectively treat this disease; 
however, a prevention method is needed to reduce the use of antibiotics. Experimental vaccines 
have been investigated for cellulitis, such as a C. perfringens and C. septicum bacterin-toxoid 
(Thachil et al., 2012), a recombinant C. septicum alpha toxin peptide vaccine (Lancto et al., 
2014), and C. septicum bacterin-toxoids (Tellez et al., 2009; Thachil et al., 2013). Vaccination 
with a C. septicum bacterin-toxoid mineral oil vaccine reduced antibiotic usage and associated 
mortalities compared to non-vaccinated controls (Thachil et al., 2013). It has been hypothesized 
that water-in-oil emulsion vaccines create a depot or repository effect which stimulates and 
provides long term interaction with the immune system and antigen, thus elevating the overall 
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immune response (Aucouturier et al., 2001). Water-in-oil emulsion vaccines consist of a 
liquid/antigenic part and an oil part which are homogenized to achieve a target droplet size and 
uniformity. Aluminum hydroxide is commonly used as an adjuvant and may be an effective by 
creating a depot effect at the site of vaccination (He et al., 2015). Mannosylated chitosan has 
been combined with multiple antigens to enhance the immune response (Hargis et al., 2015). The 
purpose of these experiments was to evaluate and compare the efficacy of multiple adjuvants 
with a C. septicum bacterin-toxoid antigen to induce an immune response under laboratory 
conditions and then test the most efficacious vaccine under commercial conditions.  
MATERIALS AND METHODS 
 
Bacterial isolates 
 
Isolation, identification, and culture of isolates used in these experiments has been previously 
described (Tellez et al., 2009).  Briefly, two Clostridium septicum (CS) isolates from fluid 
emphysematous lesions of cellulitis in commercial turkeys that died acutely were purified and 
identified using commercial anaerobic identification panels (RapID ANA II anaerobic 
identification panels, Remel Inc., Lenexa, KS). From this, an experimental bacterin/toxoid was 
produced from two CS isolates that were capable of causing lesions consistent with turkey 
cellulitis and was recovered from induced lesions, as described. The bacterin was produced from 
an anaerobic 18h tryptic soy broth and sodium thioglycollate (0.5%) culture of CS, inactivated 
by the addition of formaldehyde (Fisher, Waltham, MA) to achieve a final concentration of 
0.25%. Inactivation was timed to allow accumulation of toxin and 108 cells/mL (24- hr 
incubation) as verified by quantitative enumeration and hemolysin titration (Hang’ombe et al., 
2005).  
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CS bacterin-toxoid Vaccine Preparation  
 
Adjuvants were combined with the CS bacterin-toxoid as follows. Aluminum hydroxide (Rugby 
Labs, Duluth, GA.) was included as an adjuvant at 12% (v/v) (Experiment 1). Mannosylated 
chitosan (Hargis et al., 2015) was included at a 2:1 ratio with the bacterin-toxioid (Experiment 1 
and 2). A commercial water-in-oil adjuvant (Seppic Montanide 71R VG) was included at 70%, 
per manufacturer’s instructions (Experiment 1, 2 and 3). For the OE vaccine, the CS bacterin-
toxoid was added to oil component and homogenized over a 45 second duration at low speed 
using a PRO 200 homogenizer, (PRO Scientific Inc., Oxford, CT). Following addition of 
antigen, oil emulsion was homogenized for 5 minutes. Emulsion stability decreased when 
homogenization time continued longer than 5 minutes. Droplets size for oil emulsion vaccine 
ranged from 1-2 μm. Stability of emulsion was evaluated and verified to be stable at 4C for at 
least 30 days. Sterility was verified by spread plating 100µl of prepared vaccine on sheep blood 
agar and incubating aerobically and anaerobically at 37C for 18h.  
Indirect Enzyme-Linked Immunosorbent Assay (ELISA) 
 
The indirect enzyme-linked immunosorbent assay (ELISA) used for measuring relative antibody 
levels against the potential CS etiology has been previously described (Tellez et al., 2009). This 
assay was used to show that vaccinated turkeys had increased levels of antibodies to CS or that 
turkeys with higher levels of antibodies were less likely to contract cellulitis. The assay was 
performed similarly to previously described methods (Roberts et al., 1987; Ameiss et al., 2004; 
Hang’ombe et al., 2005). Absorbance was read at 450 nm using a commercial microplate reader 
(BioTek MQX200, BioTek Instruments Inc., Winooski, VT.). The absorbance obtained for the 
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positive control, negative control, and experimental samples was used to calculate the sample to 
positive control ratios (S/P ratios) (Brown et al., 1991; Davies et al., 2003).  
EXPERIMENTAL DESIGN 
 
Laboratory Trial  
 
Experiment 1 was conducted comparing the effects of adjuvants including aluminum hydroxide, 
mannosylated chitosan, or commercial water-in-oil adjuvant, Seppic Montanide 71R VG with 
the CS bacterin-toxoid. 100 day-of-hatch commercial cross poults were obtained from a local 
hatchery and transferred to the University of Arkansas JKS Poultry Health Laboratory 
(Fayetteville, AR). Poults (n=20 per treatment) were randomly assigned to one of five treatment 
groups and then individually neck tagged according to treatment. Treatment groups were 
subcutaneously (neck) vaccinated with respective candidate vaccines on day-of-hatch (prime) 
with 0.25mL and boosted at 5 weeks-of-age with 0.5mL. Treatment groups included 1) non-
vaccinated control, 2) alum prime + oil emulsion (OE) boost, 3) mannosylated chitosan (MCA) 
prime + MCA boost, 4) MCA prime + alum boost, 5) and an oil emulsion prime + oil emulsion 
group boost. Turkeys were comingled and provided feed and water ad libitum for the 7-week 
duration of the experiment. Serum samples were obtained at 2, 5 and 7 weeks-of-age. No 
cellulitis-associated lesions or mortalities were observed in this experiment. Vaccine injection 
site lesions were scored post-mortem by a licensed veterinarian as a 0 (not present), 1 (detectable 
but insignificant), 2 (moderate), and 3 (clinically meaningful lesions).  
Field Trial 1  
 
Experiment 2 included 3 houses (HS) with each having a non-vaccinated control and vaccinated 
group. Control turkeys were distinguished by the removal of the dewclaw and were comingled 
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with vaccinated turkeys. Vaccinated turkeys were primed at day-of-hatch with a CS 
bacterin/toxoid MCA vaccine and subcutaneously boosted at 8 weeks-of-age with the CS 
bacterin/toxoid oil emulsion vaccine (0.5mL). Allocation treatments was as follows: HS 1 
consisted of 5800 control turkeys and 4800 vaccinated turkeys, HS 2 consisted of 4800 control 
turkeys and 5000 vaccinated turkeys, and HS 3 with 4100 control turkeys and 5100 vaccinated 
turkeys. Mortality was calculated based on percent of each group.  Blood samples were obtained 
from 20 per treatment per house at 8, 12, and 16 weeks-of-age. Mortality estimates were reported 
from 13-16 weeks-of-age. Antibiotic treatment was administered when cellulitis mortalities were 
observed, however, the duration of antibiotic therapy was not provided in this trial.  
Field Trial 2  
 
Experiment 3 consisted of 6 farms with 1-4 houses per farm as described in Table 4. Non-
vaccinated control and vaccinated group were allocated evenly. Control turkeys were 
distinguished by the removal of the dewclaw and were comingled with vaccinated turkeys.  
Turkeys were subcutaneously vaccinated (0.5mL) at 8 weeks-of-age with CS toxoid oil emulsion 
vaccine. Blood samples were obtained from 10 per treatment per house at 8, 12, and 16-20 
weeks-of-age based on collection date determined by producer. Mortality estimates were 
reported from 13-21 weeks-of-age. Similar to experiment 2, antibiotic therapy was administered 
at onset of disease and duration of treatment was recorded (Table 5).  
Statistical Analysis  
 
All data were subjected to Analysis of Variance as a completely randomized design using the 
General Linear Models procedure of SAS (SAS Institute, 2002). Antibody response data is 
expressed as mean ± standard error, in all experiments. Significant differences among means 
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were determined by using Tukey’s multiple-range test (Experiment 1) at P < 0.05. Chi-squared 
test of independence (Zar, 1984) was used to determine significant (P < 0.05) differences for 
mortality. 
RESULTS AND DISCUSSION 
 
Toxoid vaccines have successfully prevented Clostridial diseases, such as blackleg in 
ruminants (Useh et al., 2006; Uzal et al., 2012). Vaccines for turkey cellulitis including a C. 
septicum bacterin-toxiod combined with an aluminum hydroxide adjuvant (Tellez et al., 2009), a 
recombinant C. septicum alpha toxin peptide (Lancto et al., 2014) and both a C. septicum 
bacterin-toxiod and C. septicum and C. perfringens bacterin-toxoid mixed with an oil emulsion 
adjuvant (Thachil et al., 2012; Thachil et al., 2013) have been evaluated and proven to have some 
protective effects. 
In experiment 1, at 2 weeks post-prime, a group vaccinated day-of-hatch with MCA CS 
bacterin-toxoid had significantly (P<0.05) higher antibody levels than the non-vaccinated 
control, but was not statistically different than vaccinated groups. At 5 weeks post-prime, turkeys 
vaccinated on day-of-hatch with the CS oil emulsion vaccine had significantly (P<0.05) higher 
antibody levels than all groups. By 7 weeks-of-age, all vaccinated groups had markedly (P<0.05) 
higher antibody levels than the control however there was no statistical difference between 
vaccinated groups. CS oil emulsion prime + CS oil emulsion boost group resulted in the most 
elevated immune response compared to all treatment groups followed by the Alum prime + CS 
oil emulsion boost group (Table 1). We identified that prime and boost vaccination with the C. 
septicum bacterin-toxoid oil emulsion vaccine elicits a more robust immune response than the 
alternatives evaluated (Table 1). This, in part, may be due to the fact that oil emulsion vaccines 
provide long term protection against the antigenic portion included in a vaccine due to the 
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accumulation of a depot at the injection site (Aucouturier et al., 2001). Antigen should be 
released slowly from this repository over an extended period thus increasing encounter of 
antigen with antigen presenting cells. Continuous interaction between antigen and antigen 
presenting cells provides constant stimulation of the immune system and subsequent antibody 
production (Awate et al., 2014). Vaccine injection sites were evaluated post mortem to determine 
if there were any lesions associated with the adjuvants tested in experiment 1. MCA prime + 
MCA boost and MCA prime + alum boost groups had no observed lesions at vaccine injection 
site. However, in the both oil emulsion vaccine groups there were lesions present at the injection 
site (Table 2). Injection site lesions associated with oil emulsion vaccination were consistent 
with lesions induced by commercial oil emulsion vaccines (data not shown). There were no 
cellulitis related morbidities or mortalities in experiment 1 (Table 2).  
In experiment 2, there was no difference in titer between the control and vaccinated 
group at 8 weeks post-prime with the CS MCA vaccine. However, at 12 and 16 weeks-of-age (4 
and 8 weeks post-boost with the CS oil emulsion vaccine), the vaccinated group had significantly 
(P<0.05) higher antibody levels than the control group in all three houses (Table 3). Vaccinated 
turkeys in experiment 2 were primed with the C. septicum MCA vaccine which may have 
stimulated a primary immune response. The prime vaccination could explain the higher antibody 
levels that were observed in the vaccinated group for this experiment.  Mortality was reported 
from 13-16 weeks-of-age although the results are complicated due to the intermittent use of 
antibiotics. In HS 1 and 2, CS-related mortalities were low in both groups and there was no 
mortality differences observed between the control and vaccinated group. However, in HS 3, 
there was a significant (P<0.001) reduction in cellulitis related mortalities in the vaccinated 
group (Table 3).  The significantly lower mortality observed in the vaccinated treatment group 
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may be a result a higher bacterial challenge being present in this house, thus the vaccinated 
group had a sufficient immune response to the C. septicum bacterin-toxoid oil emulsion vaccine 
and were protected whereas the non-vaccinated controls were naïve to the antigen. 
Experiment 3 consisted of 6 farms with 1-4 houses per farm. At vaccination (8 weeks-of-
age), there was no antibody level differences between control and vaccinated groups. At 12 
weeks-of-age (4 weeks post vaccination), vaccinated groups had a significantly (P<0.05) more 
robust immune response than the control groups. Vaccinated group antibody titers were 
significantly (P<0.05) higher than control groups at 16-20 weeks-of-age (Table 4). Mortality was 
reported between 13-21 weeks-of-age. Cellulitis-associated mortalities were significantly 
(P<0.05) lower in vaccinated groups than control groups in 5 of the 6 houses. There were 24% 
less cellulitis-related mortalities in the vaccinated groups in experiment 3 (Table 5). Similar to 
experiment 2, if antibiotic treatment was required, both the control and the vaccinated groups 
were subjected to the treatment. Previously, Thachil et al., (2013) evaluated a CS bacterin-toxoid 
oil emulsion vaccine and observed a significant reduction in antibiotic usage and cellulitis 
mortalities in the vaccinated group. Vaccinate antibody titers were elevated and had complete 
protection against C. septicum challenge while non-vaccinates had low antibody levels with 
100% mortality 24 hours post challenge (Thachil et al., 2013). This indicates that an oil emulsion 
vaccine for cellulitis can protect against experimental subcutaneous challenge (Thachil et al., 
2013).  
These data show that the C. septicum bacterin-toxoid oil emulsion vaccine used in these 
experiments elicits robust immune response and may reduce the incidence of cellulitis related 
mortalities. Vaccine efficacy without antibiotic treatment under commercial conditions is 
currently unknown.  Further studies need to be conducted to determine effectiveness of a 
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subsequent boost vaccination in a field study, protective ability of this C. septicum bacterin-
toxoid oil emulsion vaccine against experimental C. septicum challenge, and evaluation of 
vaccine efficacy without antibiotic treatment.   
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List of Tables 
 
Table 1. Antibody response to Clostridium septicum following vaccination with various CS 
bacterin-toxoid/adjuvant combinations (Experiment 1) 
  
2 weeks post-
prime 
 
5 weeks post-
prime, pre-
boost 
 
 
7 weeks post-
prime, 2 weeks 
post-boost 
 
Mortality*,1 
Control 0.14 ± 0.02b 0.44 ± 0.04b 0.34 ± 0.06 b 1/12 (8.33%) 
Alum + OE 0.16 ± 0.02 ab 0.51 ± 0.06 b 1.48 ± 0.13a 0/15 (0%) 
MCA + MCA 0.16 ± 0.03 ab 0.55 ± 0.06 b 1.30 ± 0.14 a 1/17 (5.89%) 
MCA + Alum 0.31 ± 0.05 a 0.35 ± 0.06 b 1.25 ± 0.13 a 1/17 (5.89%) 
OE + OE 0.26 ± 0.06 ab 1.06 ± 0.14 a 1.63 ± 0.17 a 1/18 (5.56%) 
a, b Indicates significant differences (P < 0.05) between treatment groups by age 
Turkeys were primed on day-of-hatch with 0.25mL and boosted at 5 weeks-of-age with respective vaccine 
1 Several neck tags were lost in each group.  Mortality was calculated on the basis of the number of birds 
with retained neck tags at the end of the experiment  
*No cellulitis lesions observed and no challenge was administered in this experiment 
 
 
 
Table 2. Localized reactions at vaccine injection site evaluated post-mortem at 7 weeks-of-age 
(Experiment 1) 
 Score 
Treatment 0 1 2 3 
Non-vaccinated Control 12/12 (100%) 0/12 (0%) 0/12 0/12 (0%) 
Alum + OE 5/15 (33%) 9/15 (60%) 1/15 (6.7%) 0/15 (0%) 
MCA + MCA 17/17 (100%) 0/17 (0%) 0/17 (0%) 0/17 (0%) 
MCA + Alum  17/17 (100%) 0/17(0%) 0/17 (0%) 0/17 (0%) 
OE + OE 6/18 (33.3%) 9/18 (50%) 3/18 (16.7%) 0/18 (0%) 
Turkeys were comingled for the duration of the trial. Injection site lesions were not evaluated for turkeys which lost 
neck tags 
Scoring: 0 (not present), 1 (detectable but insignificant), 2 (moderate), and 3 (clinically meaningful lesions) 
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Table 3. Cellulitis-related mortalities and antibody response Clostridium septicum at 8, 12, and 
16 weeks post-vaccination (Experiment 2) 
 8 weeks post-
prime, pre-
boost 
12 weeks post-
prime, 4 weeks 
post-boost 
16 weeks post-
prime, 8 weeks 
post-boost 
Late mortality 
associated with 
cellulitis 
HS 1 Control 0.25 ± 0.01 a 0.39 ± 0.05 b 0.37 ± 0.02 b 81 
HS 1 Vaccinated 0.30 ± 0.02 a 2.16 ± 0.16 a 1.57 ± 0.08 a 80 
HS 2 Control 0.25 ± 0.02 a 0.46 ± 0.09 b 0.41 ± 0.07 b 70 
HS 2 Vaccinated 0.29 ± 0.02 a 1.71 ± 0.13 a 2.40 ± 0.15 a 80 
HS 3 Control 0.24 ± 0.02 a 0.32 ± 0.03 b 0.56 ± 0.18 b 148 
HS 3 Vaccinated 0.28 ± 0.06a 1.60 ± 0.11a 2.12 ± 0.15a 78* 
a, b Indicates significant differences (P < 0.05) between control and treatment group by house 
Vaccinated turkeys were primed with CS bacterin-toxoid MCA vaccine day-of-hatch and boosted (0.5mL) with CS 
bacterin-toxoid oil emulsion vaccine at 8 weeks-of-age 
n=20/group 
*Indicates significant difference (P < 0.001) between control and vaccinated group by house  
Mortality reported between 13 and 16 weeks-of-age 
 
  
   
3
5
 
Table 4. Antibody response at 8, 12, and 16-20 weeks-of-age (Experiment 3) 
   Antibody Response (S/P) ratio 
 n/farm (# of houses) † Treatment  8 weeks 12 weeks 16-20 weeks*  
Farm 1  13608 (2) Control 0.43 ± 0.02 a 0.56 ± 0.03 b 1.28 ± 0.02 b 
  Vaccinated 0.40 ± 0.02 a 0.88 ± 0.07 a 2.01 ± 0.16 a 
Farm 2 21600 (4) Control 0.31 ± 0.01 a 0.81 ± 0.03 b 1.01 ± 0.04 b 
  Vaccinated 0.30 ± 0.01 a 1.29 ± 0.10 a 1.91 ± 0.12 a 
Farm 3 21600 (4) Control 0.37 ± 0.02 a 0.64 ± 0.02 b 1.08 ± 0.04 b 
  Vaccinated 0.38 ± 0.01 a 1.02 ± 0.06 a 2.16 ± 0.09 a 
Farm 4 6792 (1) Control 0.61 ± 0.04 a 0.77 ± 0.06 b 1.12 ± 0.11 b 
  Vaccinated 0.63 ± 0.04 a 1.15 ± 0.15 a 1.57 ± 0.15 a 
Farm 5 36288 (3) Control 0.51 ± 0.03 a 0.66 ± 0.03 b 0.98 ± 0.06 b 
  Vaccinated 0.51 ± 0.01 a 0.99 ± 0.06 a 1.39 ± 0.13 a 
Farm 6 18774 (3) Control 0.53 ± 0.02 a 0.92 ± 0.05 a 1.38 ± 0.08 a 
  Vaccinated 0.52 ± 0.02 a 1.19 ± 0.05 b 1.90 ± 0.12 b 
a, b Indicates significant differences (P < 0.05) between control and treatment group by farm 
*Collection date determined by producer  
Vaccinated turkeys were subcutaneously vaccinated (0.5mL) with CS bacterin-toxoid oil emulsion vaccine at 8 weeks-of-age 
n=10/group 
†
n/treatment was allocated evenly between control and vaccinated group for all houses 
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Table 5. Late cellulitis-associated mortalities (Experiment 3) 
 Control 
Mortality 
Vaccinated 
Mortality 
Total Late 
Mortality 
Total Late 
Mortality as % 
of Farm 
Antibiotic 
Treatment (# of 
days) 
Farm 1 131 (76%) 42 (24%)* 173 1.27% 42 
Farm 2 10 (24%)* 31(76%) 41 0.19% 14 
Farm 3 19 (86%) 3 (14%)* 22 0.10% 0 
Farm 4 160 (71%) 64 (29%)* 224 3.30% 35 
Farm 5 749 (59%) 514 (41%)* 1263 3.48% 42 
Farm 6 266 (63%) 158 (37%)* 424 2.26% 35 
Exp 2 total† 1335 (62%) 812 (38%) 2147 1.81% - 
*Indicates significant differences (P < 0.05) between control and treatment group by farm 
(%) indicative of a percent of total late mortalities  
†
Statistical analysis not conducted due to variability between farms 
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Chapter IV. Conclusion 
 
C. septicum alpha-toxin is the primary virulent toxin responsible for inducing cellulitis. 
Preventative measures, such as improved flock management and direct-fed microbials, can 
reduce the risk of disease, however antibiotic therapy is still required. An effective vaccine could 
provide immune protection for flocks if vaccinated prior to infection. Oil emulsion vaccines 
induce long term robust immunity to the antigenic portion of the vaccine, such as the C. septicum 
bacterin-toxoid evaluated in these experiments. Although booster vaccination under field 
conditions are not ideal, it may be necessary to prevent turkey cellulitis related mortalities 
without antibiotic treatment.  
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